Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family*

Received for publication, February 6, 2015, and in revised form, July 18, 2015. Published, JBC Papers in Press, July 28, 2015. DOI 10.1074/jbc.M115.643361

Kouta Niizuma‡§, Satoko Tahara-Hanaoka§¶†, Emiko Noguchi†¶†, and Akira Shibuya‡¶†

From the Departments of ‡Immunology and §Medical Genetics, Faculty of Medicine, the †Center for Tsukuba Advanced Research Alliance (TARA), the ‡Japan Science and Technology Agency, CREST, and the †Ph.D. Program in Human Biology, School of Integrative and Global Majors, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan

Background: CD300 family molecules regulate innate immune responses.

Results: We identified and characterized a novel immunoreceptor, CD300H.

Significance: CD300H may play an important role in innate immunity.

Recruitment of circulating monocytes and neutrophils to infection sites is essential for host defense against infections. Here, we identified a previously unannotated gene that encodes an immunoglobulin-like receptor, designated CD300H, which is located in the CD300 gene cluster. CD300H has a short cytoplasmic tail and associates with the signaling adaptor proteins, DAP12 and DAP10. CD300H is expressed on CD16+ monocytes and myeloid dendritic cells. Ligation of CD300H on CD16+ monocytes and myeloid dendritic cells with anti-CD300H monoclonal antibody induced the production of neutrophil chemotaxants. Interestingly, CD300H expression varied among healthy subjects, who could be classified into two groups according to “positive” and “negative” expression. Genomic sequence analysis revealed a single-nucleotide substitution (rs905709 (G → A)) at a splice donor site on intron 1 on either one or both alleles. The International HapMap Project database has demonstrated that homozygosity for the A allele of single nucleotide polymorphism (SNP) rs905709 (“negative” expression) is highly frequent in Han Chinese in Beijing, Japanese in Tokyo, and Europeans (A/A genotype frequencies 0.349, 0.167, and 0.138, respectively) but extremely rare in Sub-Saharan African populations. Together, these results suggest that CD300H may play an important role in innate immunity, at least in populations that carry the G/G or G/A genotype of CD300H.

* This work was supported in part by grants provided by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors declare that they have no conflicts of interest with the contents of this article. The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) LC013475 and LC013476.

1 To whom correspondence should be addressed. Tel.: 81-29-853-3281; Fax: 81-29-853-3410; E-mail: tokothri@md.tsukuba.ac.jp.

2 The abbreviations used are: Mo, monocytes; iMo, inflammatory Mo; pMo, patrolling Mo; intMo, intermediate Mo; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; aa, amino acid(s); MFI, mean fluorescence intensity.

Recruitment of circulating monocytes and neutrophils to infection sites is essential for host defense against infections. Here, we identified a previously unannotated gene that encodes an immunoglobulin-like receptor, designated CD300H, which is located in the CD300 gene cluster. CD300H has a short cytoplasmic tail and associates with the signaling adaptor proteins, DAP12 and DAP10. CD300H is expressed on CD16+ monocytes and myeloid dendritic cells. Ligation of CD300H on CD16+ monocytes and myeloid dendritic cells with anti-CD300H monoclonal antibody induced the production of neutrophil chemotaxants. Interestingly, CD300H expression varied among healthy subjects, who could be classified into two groups according to “positive” and “negative” expression. Genomic sequence analysis revealed a single-nucleotide substitution (rs905709 (G → A)) at a splice donor site on intron 1 on either one or both alleles. The International HapMap Project database has demonstrated that homozygosity for the A allele of single nucleotide polymorphism (SNP) rs905709 (“negative” expression) is highly frequent in Han Chinese in Beijing, Japanese in Tokyo, and Europeans (A/A genotype frequencies 0.349, 0.167, and 0.138, respectively) but extremely rare in Sub-Saharan African populations. Together, these results suggest that CD300H may play an important role in innate immunity, at least in populations that carry the G/G or G/A genotype of CD300H.

* This work was supported in part by grants provided by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors declare that they have no conflicts of interest with the contents of this article. The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) LC013475 and LC013476.

1 To whom correspondence should be addressed. Tel.: 81-29-853-3281; Fax: 81-29-853-3410; E-mail: tokothri@md.tsukuba.ac.jp.

2 The abbreviations used are: Mo, monocytes; iMo, inflammatory Mo; pMo, patrolling Mo; intMo, intermediate Mo; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; aa, amino acid(s); MFI, mean fluorescence intensity.

Recruitment of circulating monocytes and neutrophils to infection sites is essential for host defense against infections. Here, we identified a previously unannotated gene that encodes an immunoglobulin-like receptor, designated CD300H, which is located in the CD300 gene cluster. CD300H has a short cytoplasmic tail and associates with the signaling adaptor proteins, DAP12 and DAP10. CD300H is expressed on CD16+ monocytes and myeloid dendritic cells. Ligation of CD300H on CD16+ monocytes and myeloid dendritic cells with anti-CD300H monoclonal antibody induced the production of neutrophil chemotaxants. Interestingly, CD300H expression varied among healthy subjects, who could be classified into two groups according to “positive” and “negative” expression. Genomic sequence analysis revealed a single-nucleotide substitution (rs905709 (G → A)) at a splice donor site on intron 1 on either one or both alleles. The International HapMap Project database has demonstrated that homozygosity for the A allele of single nucleotide polymorphism (SNP) rs905709 (“negative” expression) is highly frequent in Han Chinese in Beijing, Japanese in Tokyo, and Europeans (A/A genotype frequencies 0.349, 0.167, and 0.138, respectively) but extremely rare in Sub-Saharan African populations. Together, these results suggest that CD300H may play an important role in innate immunity, at least in populations that carry the G/G or G/A genotype of CD300H.

* This work was supported in part by grants provided by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors declare that they have no conflicts of interest with the contents of this article. The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) LC013475 and LC013476.

1 To whom correspondence should be addressed. Tel.: 81-29-853-3281; Fax: 81-29-853-3410; E-mail: tokothri@md.tsukuba.ac.jp.

2 The abbreviations used are: Mo, monocytes; iMo, inflammatory Mo; pMo, patrolling Mo; intMo, intermediate Mo; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; aa, amino acid(s); MFI, mean fluorescence intensity.

Recruitment of circulating monocytes and neutrophils to infection sites is essential for host defense against infections. Here, we identified a previously unannotated gene that encodes an immunoglobulin-like receptor, designated CD300H, which is located in the CD300 gene cluster. CD300H has a short cytoplasmic tail and associates with the signaling adaptor proteins, DAP12 and DAP10. CD300H is expressed on CD16+ monocytes and myeloid dendritic cells. Ligation of CD300H on CD16+ monocytes and myeloid dendritic cells with anti-CD300H monoclonal antibody induced the production of neutrophil chemotaxants. Interestingly, CD300H expression varied among healthy subjects, who could be classified into two groups according to “positive” and “negative” expression. Genomic sequence analysis revealed a single-nucleotide substitution (rs905709 (G → A)) at a splice donor site on intron 1 on either one or both alleles. The International HapMap Project database has demonstrated that homozygosity for the A allele of single nucleotide polymorphism (SNP) rs905709 (“negative” expression) is highly frequent in Han Chinese in Beijing, Japanese in Tokyo, and Europeans (A/A genotype frequencies 0.349, 0.167, and 0.138, respectively) but extremely rare in Sub-Saharan African populations. Together, these results suggest that CD300H may play an important role in innate immunity, at least in populations that carry the G/G or G/A genotype of CD300H.

* This work was supported in part by grants provided by the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The authors declare that they have no conflicts of interest with the contents of this article. The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EBI Data Bank with accession number(s) LC013475 and LC013476.

1 To whom correspondence should be addressed. Tel.: 81-29-853-3281; Fax: 81-29-853-3410; E-mail: tokothri@md.tsukuba.ac.jp.

2 The abbreviations used are: Mo, monocytes; iMo, inflammatory Mo; pMo, patrolling Mo; intMo, intermediate Mo; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; aa, amino acid(s); MFI, mean fluorescence intensity.
Identification and Characterization of CD300H

Cloning of Human CD300H cDNA—Full-length cDNA of human CD300H was isolated from human CD14+ monocyte-derived cDNA by reverse transcription-polymerase chain reaction (RT-PCR) using CD300H-specific primers (5'-ATGACCGAGGGCTGGGCC-3' and 5'-TCATGACTCTGTCCAAGGAG-3').

Generation of Fc Fusion Protein—Fusion proteins of the entire extracellular domains of CD300H, CD300A, and CD300C with the Fc portion of human IgG1 (CD300H-Fc, CD300A-Fc, and CD300C-Fc, respectively) were generated as described previously (26).

Antibodies and Flow Cytometry Analyses—Monoclonal antibody (mAb) against CD300H (TX93; mouse IgG2a) was generated in our laboratory by immunizing mice with BW5147 transfectant expressing CD300C, as described previously (12). mAb against CD300C (TX47; mouse IgG1) was generated by immunizing mice with BW5147 transfected expressing CD300C, as described previously (12). mAb against CD300A and CD300C (TX49; mouse IgG1) was generated in our laboratory, as described previously (27). mAbs specific to human CD3 (clone UCHT1), CD14 (clone M5E2), CD56 (clone B159), CD11c (clone B-ly6), CD16 (clone 3G8), HLA-DR (clone G46-6), CD40 (clone 5C3), CD80 (clone BB1), and CD86 (clone 2331) were purchased from BD Biosciences (San Jose, CA). mAbs specific to human CD11c (clone AC145), CD203c (clone FR3-16A11), and CD304 (clone ADS-17F6) were purchased from Miltenyi Biotec (Auburn, CA). Flow cytometry analyses were performed with a FACS Fortessa flow cytometer (BD Biosciences). FlowJo software (Tree Star, Ashland, OR) was used for data analyses.
followed by horseradish peroxidase (HRP)-conjugated anti-
rabbit IgG (eB182, eBioscience, San Diego, CA), anti-mouse
IgG (eB144, eBioscience), or anti-rat IgG (NA935, GE Health-
care UK Ltd., Buckinghamshire, UK).

Stimulation of CD300H for Cytokine and Chemokine
Production—CD16+/H11001 Mo (5 \times 10^4 or 1 \times 10^5/well), CD16+/H11002 Mo, and CD11c+/H11001 DCs (5 \times 10^5/well) were plated into
96-well flat-bottom plates precoated with 10 \mu g/ml F(ab')_2
fragments of either anti-CD300H (TX93) or control mouse
IgG and cultured for 4 or 24 h at 37 °C in 5% CO_2. TNF-α
concentration in the culture supernatants was measured
with ELISA kits purchased from BD Biosciences; concentra-
tions of IL-12p70, TNF-α, IL-10, IL-6, IL-1β, and IL-8 in the
culture supernatants were measured with a BD\textsuperscript{TM}
cytometric bead array (BD Biosciences); and the mRNAs of
IL6, CXCL1, CXCL2, CXCL5, and CXCL8 were quantified by real-
time quantitative PCR. The sequences of the specific primers
were as follows: IL-6 forward, 5'-GATGAGTACAAAAAGT-
CCTGATCCA-3'; IL-6 reverse, 5'-CTGCAGCCACTGGTT-
TCTGT-3'; CXCL1 forward, 5'-TCCTGCATCCCCCATAG-
TAA-3'; CXCL1 reverse, 5'-CTTGGAGCAACAGCCAC-
AGT-3'; CXCL2 forward, 5'-CTTTGCTCAACCCCGCA-
TCG-3'; CXCL2 reverse, 5'-TCCTCCAGGAACAGCCAC-
CCA-3'; CXCL5 forward, 5'-TTGCCCATAGGGCCAC-
AGT-3'; CXCL5 reverse, 5'-TTTCCATGCCTGCTTCC-
TCG-3'; CXCL8 forward, 5'-AGACAGCAGACACACA-
GAC-3'; CXCL8 reverse, 5'-CACAGTGAGATGG-
TTCCCTCC-3'.

cDNA Synthesis and RT-PCR—Total RNA was extracted with
Isogen reagent (Nippon Gene, Tokyo, Japan), and cDNA
was synthesized by using a High-Capacity RNA-to-cDNA Kit
(Applied Biosystems, Foster City, CA). Real-time RT-PCR was
performed with SYBR Green master mix (Applied Biosystems).
Expression of each target gene was normalized against that of

---

**FIGURE 1. Molecular characteristics of CD300H.**

**A**, localization on mouse and human CD300 family gene maps. Mouse and human family genes are mapped on chromosomes 11 and 17, respectively. **B**, amino acid sequences of CD300H and CD300Hs. Numbers in parentheses (left), aa positions; underlining, putative leader and transmembrane sequences; circles, potential N-linked glycosylation sites in the extracellular domain and the charged aa residue in the transmembrane region; *, cysteine residues potentially involved in disulfide bonding of the immunoglobulin-like domains. **C**, schematic diagram of CD300H (left) and CD300Hs (right) proteins. The pair of cysteine residues in the extracellular portion is potentially able to participate in intrachain disulfide bonding for the formation of Ig-like domains. **D**, phylogenetic tree showing the relationships among the Ig-like domain amino acid sequences of human CD300 molecules. Each neighbor-joining phylogenetic tree was generated by aligning the translated sequences of the open reading frames for CD300 proteins by using the ClustalW algorithm.
Characterization of the anti-CD300H monoclonal antibody, TX93. A, flow cytometry of THP-1 cells or THP-1 transfectants expressing CD300H (5 x 10^5 cells/experiment) were stained with biotinylated control mouse immunoglobulin (shaded) or anti-CD300H (TX93) (thick lines) followed by allophycocyanin-conjugated streptavidin. B, flow cytometry of BW5147 transfectants expressing CD300A or CD300C or 2B4 transfectants expressing CD300H (5 x 10^5 cells/experiment) were stained with control mouse immunoglobulin (shaded), TX93, anti-CD300C (TX47), or anti-CD300A and CD300C (TX49) (thick lines), followed by phycoerythrin-conjugated goat F(ab')2 fragment anti-mouse IgG. C, microtitre plates coated with control human IgG, CD300H-Fc, CD300A-Fc, or CD300C-Fc were incubated with control mouse IgG, TX93, TX47, or TX49, and binding was analyzed by ELISA. Data are representative of two independent experiments.

Identification and Characterization of CD300H

GAPDH (primer sequences 5'-CTTCACCACCAGGAGAACGGC-3' and 5'-GGCAGTGATCATGAAG-3').

Neutrophil Migration Assay—Neutrophils were isolated from whole blood with Polymorphprep (Axis-Shield) in accordance with the manufacturer's protocol. Supernatant obtained from TX93-stimulated CD16^+ Mo was added to the lower compartment of 96-well Transwell plates (pore size 3.0 μm; Corning, Inc.) at a total volume of 235 μl/well. Neutrophils (1 x 10^6) were placed in the upper compartment at a total volume of 75 μl, and then the plates were incubated for 30 min at 37 °C in 5% CO2. Cells in the lower compartment were collected and counted by using a Guava easyCyte Mini flow cytometer (Millipore).

Statistical Analyses—The unpaired Student’s t test was used for statistical analyses. p values of <0.05 were considered statistically significant. All statistical analyses were carried out using GraphPad Prism version 5.0c software (GraphPad Software, San Diego, CA).

Results

Cloning of the Gene Encoding Human CD300H—In our search for a human homolog of MAIR-II in the National Center for Biotechnology Information database, we found a previously unannotated gene located in the human CD300 gene cluster on chromosome 17 (Fig. 1A). We isolated full-length cDNA from human CD14^+ Mo-derived cDNA by RT-PCR. Sequence analysis revealed that an open reading frame of 603 bp encoded a type I transmembrane receptor, which contained a 20-amino acid (aa) leader sequence, a 148-aa extracellular region containing an Ig-like domain, a 23-aa transmembrane region, and a 10-aa cytoplasmic domain with no signaling motif (Fig. 1B). The Ig-like domain contained a potential N-glycosylation site. The transmembrane domain contained a positively charged lysine residue (Fig. 1C). Because this homolog was the eighth member of the human CD300 family of receptors, we termed it CD300H. We also identified a splicing variant that lacked a transmembrane domain; we called this variant CD300Hs (Fig. 1, B and C). A database search demonstrated that CD300H had 44% amino acid identity with mouse MAIR-II/CLM-4/LMIR2 and CD300C/CLM-6, but it had lower rates of identity with CD300e/CLM-2/LMIR6 (42%), CD300d/CLM-5/LMIR4 (40%), CD300lb/CLM-7/LMIR5 (35%), and CD300lg/CLM-9 (35%) among the non-immunoreceptor tyrosine-based inhibitory motif-bearing receptors. The gene encoding CD300H was located between CD300C and CD300LD on human chromosome 17q25.1 (Fig. 1A). We analyzed the degree of identity of the extracellular Ig domain of CD300H with the sequences of CD300 family members and constructed a molecular phylogenetic tree by using ClustalW2 phylogeny. The Ig-like domains of CD300A and CD300C had the greatest identity (53%) with that of CD300H; other members of the family had lower identity levels (Fig. 1D).

Expression of CD300H—To investigate the cellular distribution of CD300H, we generated a mAb against CD300H (clone TX93) and analyzed its specificity. TX47 and TX49 were previously generated mAbs against CD300C and against CD300A and CD300C, respectively (Fig. 2, B and C) (27). Although CD300H had a high level of identity with CD300A and CD300C, TX93 mAb bound specifically to CD300H-expressing THP-1 and 2B4 transfectants but not to CD300A- or CD300C-expressing BW5147 transfectants (Fig. 2, A and B). In addition, TX93 mAb bound to CD300H-Fc fusion protein but not to CD300A-Fc or CD300C-Fc protein (Fig. 2C). These results indicated that TX93 mAb specifically recognized CD300H.

Flow cytometry analyses of human peripheral blood cells demonstrated that CD300H was expressed on myeloid lineage cells, including CD16^+ Mo (Fig. 3, E and H) and myeloid DCs (n = 9; Fig. 3, C and H) but not on plasmacytoid DCs (n = 3; Fig.
CD300H was not expressed on lymphocytes (T cells, B cells, and NK cells) or granulocytes (eosinophils, neutrophils, and basophils). CD16+ Mo can be divided into two subsets (CD14dimCD16+ and CD14+CD16+ Mo) on the basis of their CD14 expression; mean fluorescence intensity (MFI) of CD300H expression was comparable between these subsets (p = 0.5816, n = 13 for each; Fig. 3, E and H). Compared with CD14dimCD16− and CD14−CD16− Mo, CD16− Mo (n = 13) exhibited a significantly lower level of CD300H expression (p = 0.0234 and p = 0.0270, respectively; Fig. 3, E and H).

Individual Differences in CD300H Expression—Genomic DNA database analysis demonstrated that CD300H consisted of four exons (Fig. 4A), but the gene encoding CD300H lacked exon 3, which encoded the transmembrane region. Interestingly, we observed that 4 of the 13 individuals examined in Fig. 3 showed no detectable expression of CD300H on CD16+ Mo (Fig. 3H, open circles). Genomic DNA analyses of these individuals demonstrated a single-nucleotide substitution (rs905709; 3D). By contrast, CD300H was not expressed on lymphocytes (T cells, B cells, and NK cells) (n = 3 for each; Fig. 3, A and B) or granulocytes (eosinophils, neutrophils, and basophils) (n = 3 for each; Fig. 3, F and G). CD16+ Mo can be divided into two subsets (namely CD14dimCD16+ and CD14+CD16+ Mo) on the basis of their CD14 expression; mean fluorescence intensity (MFI) of CD300H expression was comparable between these subsets (p = 0.5816, n = 13 for each; Fig. 3, E and H). Compared with CD14dimCD16− and CD14−CD16− Mo, CD16− Mo (n = 13) exhibited a significantly lower level of CD300H expression (p = 0.0234 and p = 0.0270, respectively; Fig. 3, E and H).
G\rightarrow A) of CD300H, which abolished the intron 1 donor splice site (Fig. 4A). This can lead to loss of CD300H transcript expression through the action of nonsense-mediated mRNA decay machinery (30). Indeed, persons carrying the rs905709 A/A genotype showed a loss of CD300H transcripts (Fig. 4B) and protein (Figs. 3H and 4C). In contrast, CD16\xrightarrow{+} Mo derived from subjects with a G/A or G/G genotype expressed the CD300H transcript (Fig. 4B) and protein on their cell surfaces (Figs. 3H and 4C). The A/A genotype frequency of rs905709 differed significantly in the different ethnic populations and is observed at high frequency in Han Chinese in Beijing (HCB), Japanese in Tokyo (JPT), and CEPH (Utah Residents with Northern and Western European Ancestry, CEU) populations (A/A genotype frequencies 0.349, 0.167, and 0.138, respectively). However, it is extremely rare in Yoruba in Ibadan, Nigeria (YRI) (Fig. 4D) (31).

CD300H Associates with DAP12 and DAP10 in U937 Cells—To analyze the biochemical characteristics of CD300H, we generated a BW5147 transfectant stably expressing FLAG-tagged CD300H at the N terminus. Immunoprecipitation with anti-FLAG antibody revealed that human CD300H had a molecular mass of \sim 25 \text{kDa} under reducing conditions and \sim 50 \text{kDa} under non-reducing conditions (Fig. 5B), suggesting that CD300H forms dimeric structure. To determine whether CD300H forms homodimeric or heterodimeric structure, we generated BW5147 transfectant simultaneously expressing FLAG-tagged and hemagglutinin (HA)-tagged CD300H and performed a co-immunoprecipitation assay. We found that HA-tagged CD300H was not co-immunoprecipitated with FLAG-tagged CD300H and vice versa (Fig. 5B), suggesting that CD300H forms heterodimeric structure with an undetermined molecule with a molecular mass of \sim 25 \text{kDa} expressed in BW5147 cells.

Next, we analyzed to determine whether CD300Hs is a secreted form of CD300H. We performed immunoblot analysis of culture supernatant of 293T transfectant transiently expressing FLAG-tagged and hemagglutinin (HA)-tagged CD300H and performed a co-immunoprecipitation assay. We found that HA-tagged CD300H was not co-immunoprecipitated with FLAG-tagged CD300H and vice versa (Fig. 5B), suggesting that CD300H forms heterodimeric structure with an undetermined molecule with a molecular mass of \sim 25 \text{kDa} expressed in BW5147 cells.

Identification and Characterization of CD300H
CD300H was co-immunoprecipitated with endogenous DAP12 and DAP10, and vice versa, but not with FcγRI chain, in U937 cells (Fig. 5D). This result indicates that, unlike mouse MAIR-II, CD300H associates with DAP12 but not with the FcγRI chain in U937 cells.

**CD300H Transduces an Activating Signal in CD16+ Mo**—Our findings that CD300H was expressed on CD16+ Mo and was associated with DAP12 and DAP10 in U937 cell line suggested that CD300H was an activating receptor on CD16+ Mo. Human CD16+ Mo consists of two distinct subsets. CD14dimCD16+ Mo resemble murine Ly6Clow Mo (5), which are designated pMo and produce chemokines. On the other hand, CD14+CD16+ Mo are designated as intMo (32), main producers of inflammatory cytokines, such as TNF-α and IL-1β (33). Therefore, we investigated whether CD300H mediated signaling for inflammatory cytokine and chemokine production in CD16+ Mo. We sorted CD16+ Mo from the PBMCs of healthy donors with the G/G (CD300H+/+) or A/A genotype (CD300H−/−) and then stimulated them with plate-coated F(ab’)2 fragments of TX93 mAb or control Ig (Fig. 6, A and B). Stimulation of CD300H+/+CD16+ Mo with TX93 mAb induced significantly more TNF-α and IL-6 production than did stimulation with control Ig. In contrast, stimulation with TX93 mAb did not increase cytokine production by CD300H−/−CD16+ Mo compared with stimulation with control Ig (Fig. 6, B and C). Thus, CD300H transduces an activating signal for cytokine production in CD16+ Mo. A recent study has demonstrated that murine Ly6Clow Mo recruit neutrophils in a TLR7-dependent manner to mediate focal necrosis of endothelial cells (6). CD16+ Mo produce chemoattractants for neutrophils. To examine whether CD300H is involved in this process, CD16+ Mo were stimulated with plate-coated F(ab’)2 fragments of TX93 mAb or control Ig for 24 h; the culture supernatant was then plated in the lower compartment of a Transwell, and neutrophils derived from the peripheral blood were added to the upper compartment. In the case of CD300H+/+CD16+ Mo but not CD300H−/−CD16+ Mo, the average number of neutrophils that migrated from the upper to the lower compartment upon
Identification and Characterization of CD300H

TX93 mAb stimulation was significantly greater than that with control Ig-stimulated culture supernatant (~1.3-fold increase; p < 0.05) (Fig. 6D). These results suggested that CD300H mediated a signal for the production of a neutrophil chemoattractant. Indeed, the expression of CXCL8, CXCL1, CXCL2, and CXCL5, which encode chemokines for neutrophil attraction, was significantly greater in CD300H+ Mo, than in the controls after stimulation with plate-coated F(ab)2 fragments of TX93 mAb (Fig. 6E).

CD300H Had No Effect on IL-8 Production in CD16− Mo—Because CD16− Mo also expresses CD300H (Fig. 3E), we analyzed the CD300H activity on CD16− CD14+ classical Mo sorted from the peripheral blood from donors with the G/G (CD300H+) or A/A genotype (CD300H−). We analyzed the production of cytokines, including CXCL8 (IL-8), IL-12p70, TNF-α, IL-10, IL-6, and IL-1β, after stimulation with anti-CD300H mAb by using cytometric bead array. However, we could not detect a significant amount of cytokines except for IL-8 and observed no significant differences in IL-8 production between stimulation with control antibody and anti-CD300H mAb (Fig. 6, F and G). This might be the result of the low level of CD300H expression on CD16− Mo compared with CD16+ Mo.

CD300H Transduces an Activating Signal in CD11c+ DC—CD11c+ DCs also express CD300H at a level comparable with CD16+ Mo. We addressed whether CD300H transduces activating signal in CD11c+ DCs. We purified CD11c+ cells by the MACS sorting system (Fig. 7A), stimulated them with plate-coated F(ab)2 fragment of TX93 mAb, and analyzed surface expression of co-stimulatory molecule and cytokine production by flow cytometry. We found that TX93 stimulation did not enhance the expression level of co-stimulatory molecules, such as CD40, CD86, CD80, and HLA-DR, on the G/G genotype (CD300H+)-derived CD11c+ DCs (Fig. 7B). However, CD11c+ DCs from G/G genotype, but not A/A genotype (CD300H−), produced IL-8 upon CD300H stimulation (Fig. 7C). These results indicate that CD300H induced IL-8 production by CD16+ Mo and CD11c+ DCs and may contribute to neutrophil attraction.

Discussion

We identified and characterized a new member of the human CD300 family of immunoreceptors, which we designated CD300H. It is expressed on CD14+CD16+ intMo and CD14dimCD16+ pMo in the peripheral blood and transduces an activating signal for the production of inflammatory cyto-

FIGURE 6. CD300H ligation in CD16+ Mo induces cytokine and chemokine secretion. CD16+ Mo (A–E) and CD16− Mo (F and G) were isolated from peripheral blood mononuclear cells by using the MACS system. Their purity was then analyzed by using flow cytometry (A and F). MACS-isolated Mo from G/G (CD300H+) or A/A (CD300H−) genotype donors were stimulated with plate-coated F(ab)2 fragment of TX93 or control Ig for 24 h (B, D, and G) or 4 h (C and E). Culture supernatant was analyzed by ELISA (B) or subjected to neutrophil migration assay (D) or cytometric bead array (G). Cells were analyzed for IL-6 (C) and chemokine (E) expression by using quantitative polymerase chain reaction. In D, culture supernatant was transferred to the lower compartment of transwells, and neutrophils were placed in the upper compartment. This was followed by a 30-min incubation. *, p < 0.05; **, p < 0.01; ***, p < 0.001; NS, not significant. All data are representative of three independent experiments. Data in C and E are shown as mean ± S.D. (error bars) of four (CD300H+) and three (CD300H−) different donors.
kines (TNF-α and IL-6) and chemokines (CXCL1, CXCL2, CXCL5, and IL-8) by CD16+ Mo. In addition, CD300H induces IL-8 production by CD11c+ DC. Importantly, we demonstrated that CD300H plays an important role in host immunity against bacterial and viral infections.

Despite recent progress in human Mo studies, the physiological roles of CD16+ Mo have not been fully elucidated. One recent report described a healthy family with CD16+ Mo deficiency in the blood (34), suggesting that the function of CD16+ Mo is redundant. In accordance with this idea, we also found a subpopulation of healthy people whose CD16+ Mo did not express CD300H, suggesting that CD300H plays an important role in host immunity against bacterial and viral infections.

CD300H has a splicing variant, CD300Hs, which lacks the transmembrane domain. We found that CD300Hs is a secreted form of CD300H. Recent findings demonstrated that activating immunoglobulin-like receptors CD300b and triggering receptor expressed on myeloid cells (TREM-1) also produce soluble forms sCD300b and sTREM-1, respectively, by proteolytic cleavage (40, 41). Whereas sCD300b amplifies LPS-induced inflammation (40, 42), sTREM-1 attenuates excessive inflammatory response by counterregulating TREM-1 (41), probably by acting as a decoy receptor, as observed in the TNF-α system (43). Therefore, expression of CD300Hs may modulate CD300H-mediated inflammatory responses in vivo.

Our studies suggested that CD300H may form a heterodimeric structure in mouse T cell lymphoma, BW5147. Recent evidence demonstrated that CD300C forms either a homo-
dimer or heterodimer with all CD300 family members. Although these dimer formations require Ig-like domains, CD300C did not bind other Ig-like receptors, such as TREM-1 and CD28 (44) (45). The Ig-like domain of CD300H has 53% homology to that of CD300C, suggesting that CD300H may also form heterodimer with mouse CD300 family members expressed on the BW5147 cell line. Because we did not detect surface expression of mouse CD300a, MAIR-II, and CD300f on BW5147 cells by flow cytometry using TX41 (12), TX52 (46), and TX70 (15) mAbs, respectively (data not shown), CD300H may interact with mouse CD300 family members other than these Ig-like receptors. Unlike CD300C, CD300H has a positively charged lysine residue in its transmembrane region and interacts with DAP12 and DAP10. Thus, CD300H may be able to mediate an activating signal upon ligand binding. However, the heterodimer of CD300H with other CD300 receptors may positively or negatively modulate the signaling.

To elucidate the physiological roles of CD300H on CD16+ pMo in vivo, the counterpart of CD300H in mice needs to be identified. Although we identified CD300H in our search for a human homolog of MAIR-II, there are several differences between MAIR-II and CD300H. First, MAIR-II inhibits B-cell receptor-mediated signaling in B cells (47), whereas CD300H expression on human peripheral blood B cells was not detected by flow cytometry using TX93 mAb (Fig. 3). Second, MAIR-II is a unique receptor that binds to either DAP12 or FcERIγ; however, CD300H did not show an association with FcERIγ in U937 cells. Third, CD300H is located adjacent to CD300C on human chromosome 17, whereas Cd300ld/MAIR-IV/LMIR4/Clnm-5, but not MAIR-II, is located adjacent to Cd300c on mouse chromosome 11. Recent studies have demonstrated that CD300 family receptors recognize lipids, such as phosphatidylserine, ceramide, and lipoprotein, as ligands that mediate signals in mast cells and macrophages via these receptors (48–50). We and others reported that human CD300A binds to phosphatidylserine and phosphatidylethanolamine (11, 27, 50). Because CD300H has high amino acid identity with CD300A, we assessed whether CD300H also binds to phosphatidylserine and phosphatidylethanolamine by dot blot analyses using a lipid-bound membrane. However, CD300H bound to neither phosphatidylserine nor phosphatidylethanolamine (data not shown). Future studies are required for identification of a ligand for CD300H to understand the function of CD300H in vitro and in vivo.

Author Contributions—K. N. conducted the experiments and analyzed the data. S. T.-H. designed the experiments, analyzed the data, and wrote the paper. E. N. analyzed the data. A. S. supervised the overall project and wrote the paper.

Acknowledgments—We thank N. Akaboshi and K. Hayashi for technical assistance, Jun Ohashi (University of Tokyo) for helpful discussions, S. Mitsuiishi and Y. Nomura for secretarial assistance, and the members of the laboratory for discussions.

References
1. Soehnlein, O., and Lindbom, L. (2010) Phagocyte partnership during the onset and resolution of inflammation. Nat. Rev. Immunol. 10, 427–439
2. Shi, C., and Pamer, E. G. (2011) Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 11, 762–774
3. Gordon, S., and Taylor, P. R. (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953–964
4. Cros, I., Cagnard, N., Woollard, K., Patey, N., Zhang, S. Y., Senechal, B., Puel, A., Biwasser, S. K., Moshous, D., Picard, C., Jais, J. P., D’Cruz, D., Casanova, J. L., Trouillet, C., and Geissmann, F. (2010) Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33, 375–386
5. Auffray, C., Fogg, D., Garfa, M., Elain, G., Join-Lambert, O., Kayal, S., Sarnacki, S., Cumano, A., Lauvau, G., and Geissmann, F. (2007) Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317, 666–670
6. Carlin, L. M., Stamatiades, E. G., Auffray, C., Hanna, R. N., Glover, L., Vizcay-Barrena, G., Hedrick, C. C., Cook, H. T., Diebold, S., and Geissmann, F. (2013) Nr4a1-dependent Ly6Clow monocytes monitor endothelial cells and orchestrate their discharge. Cell 153, 362–375
7. Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D. N., Leenen, P. J., Liu, Y. J., MacPherson, G., Randolph, G. J., Scheberich, J., Schmitz, J., Shortman, K., Sozzani, S., Strobl, H., Zembla, M., Austyn, J. M., and Lutz, M. B. (2010) Nomenclature of monocytes and dendritic cells in blood. Blood 116, e74–e80
8. Wong, K. L., Yeap, W. H., Tai, J. I., Ong, S. M., Deng, T. M., and Wong, S. C. (2012) The three human monocyte subsets: implications for health and disease. Immunol. Res. 53, 41–57
9. Wong, K. L., Tai, J. I., Wong, W. C., Han, H., Sem, X., Yeap, W. H., Kourilsky, P., and Wong, S. C. (2011) Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 118, e16–e31
10. Shibuya, A., Nakahashi-Oda, C., and Tahara-Hanaoka, S. (2009) Regulation of immune responses by the activating and inhibitory myeloid-associated immunoglobulin-like receptors (MAIR) (CD300). Imnune Netw. 9, 41–45
11. Borrego, F. (2013) The CD300 molecules: an emerging family of regulators of the immune system. Blood 121, 1951–1960
12. Yotsumoto, K., Okoshi, Y., Shibuya, K., Yamazaki, S., Tahara-Hanaoka, S., Honda, S., Osaka, M., Kuroiwa, A., Matsuda, Y., Tenen, D. G., Iwama, A., Nakauchi, H., and Shibuya, A. (2003) Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and MAIR-II, regulate mast cell and macrophage activation. J. Exp. Med. 198, 223–233
13. Kumagai, H., Oki, T., Tamitsu, K., Feng, S. Z., Ono, M., Nakajima, H., Bao, Y. C., Kawakami, Y., Nagayoshi, K., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Kawakami, T., and Kitamura, T. (2003) Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. Biochem. Biophys. Res. Commun. 307, 719–729
14. Moshkovits, I., Shik, D., Itan, M., Karo-Atar, D., Bernshtein, B., Hershko, A. Y., van Lookeren Campagne, M., and Munitz, A. (2014) CMRF35-like molecule 1 (CLM-1) regulates eosinophil homeostasis by suppressing cellular chemotaxis. Mucosal Immunol. 7, 292–303
15. Can, I., Tahara-Hanaoka, S., Hitomi, K., Nakano, T., Nakahashi-Oda, C., Kurita, N., Honda, S., Shibuya, K., and Shibuya, A. (2008) Caspase-independent cell death by CD300LF (MAIR-V), an inhibitory immunoglobulin-like receptor on myeloid cells. J. Immunol. 180, 207–213
16. Can, I., Tahara-Hanaoka, S., and Shibuya, A. (2008) Expression of a splicing isoform of MAIR-V (CD300LF), an inhibitory immunoglobulin-like receptor on myeloid cells. Hybridoma 27, 59–61
17. Izawa, K., Kitaura, J., Yamanishi, Y., Matsuoka, T., Oki, T., Shibata, F., Kumagai, H., Nakajima, H., Maeda-Yamamoto, M., Hauchini, J. P., Tybulewicz, V. L., Takai, T., and Kitamura, T. (2007) Functional analysis of activating receptor LMR1 as a counterpart of inhibitory receptor LMR3. J. Biol. Chem. 282, 17997–18008
18. Izawa, K., Kitaura, J., Yamanishi, Y., Matsuoka, T., Kaitani, A., Sugisuchi, M., Takahashi, M., Maehara, A., Enomoto, Y., Oki, T., Takai, T., and Kitamura, T. (2009) Activating and inhibitory signal from an inhibitory receptor LMR3/CLM-1: LMR3 augments lipopolysaccharide response through association with FcRγ in mast cells. J. Immunol. 183, 925–936
19. Izawa, K., Yamanishi, Y., Maehara, A., Takahashi, M., Isobe, M., Ito, S.
